Novavax, Moderna trade flat as WHO downplays Russia's plague death
Novavax (NVAX) and Moderna (MRNA), among other pandemic-era stocks, showed little movement in premarket trading after the World Health Organization (WHO) reported that Russian officials had traced all contacts of a research lab employee who died from the plague. The WHO downplayed concerns about an outbreak, stating there was no risk to the general public. The muted market reaction suggests investors are not overly concerned by the incident given the reassurances provided by health authorities. These biotech firms have been closely watched since the pandemic but remain sensitive to global health developments and regulatory updates. Despite the lack of immediate impact, continued monitoring is expected as any escalation in public health threats could influence investor sentiment toward vaccine developers.
Topics: market reaction plague case WHO